黑料网

Cencora (NYSE: COR) has completed its previously announced acquisition of Retina Consultants of America (RCA), acquiring approximately 85% interest in the leading management services organization of retina specialists. The remaining minority equity interest is retained by RCA physicians and management team members.

The transaction involved a cash outlay of $4.4 billion at closing, subject to post-closing price adjustments. This amount includes equity rollover, cash capitalization of RCA, transaction fees, expenses, and debt repayment.

The strategic acquisition strengthens Cencora's specialty leadership position and expands its MSO solutions, aiming to create differentiated value for stakeholders, including physicians and patients. Following the acquisition, Cencora has raised its Adjusted Diluted EPS guidance range to $15.15 to $15.45 for Fiscal 2025.

Cencora (NYSE: COR) has successfully closed a public offering of senior notes totaling $1.8 billion. The offering consists of three tranches: $500 million of 4.625% notes due 2027, $600 million of 4.850% notes due 2029, and $700 million of 5.150% notes due 2035.

The proceeds will be used to finance the acquisition of the majority stake in Retina Consultants of America, related fees, and general corporate purposes. The offering was managed by BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, and Wells Fargo Securities.

Cencora (NYSE: COR) has announced pricing for three senior notes offerings totaling $1.8 billion: $500 million of 4.625% notes due 2027, $600 million of 4.850% notes due 2029, and $700 million of 5.150% notes due 2035. The offering, expected to close on December 9, 2024, will fund the acquisition of Retina Consultants of America's majority stake and general corporate purposes. The offering is managed by BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, and Wells Fargo Securities.

Cencora (NYSE: COR) reported Q4 fiscal 2024 revenue of $79.1 billion, up 14.7% year-over-year, with full-year revenue reaching $294.0 billion, a 12.1% increase. Q4 GAAP diluted EPS was $0.02, while adjusted diluted EPS grew 16.8% to $3.34. For fiscal 2024, GAAP diluted EPS decreased 11.7% to $7.53, while adjusted diluted EPS increased 14.8% to $13.76.

The company increased its quarterly dividend by 8% to $0.55 per share and announced the acquisition of Retina Consultants of America. U.S. Healthcare Solutions revenue grew 15.7% to $71.7 billion, while International Healthcare Solutions revenue increased 5.5% to $7.4 billion in Q4.

Cencora (NYSE: COR) has announced a definitive agreement to acquire Retina Consultants of America (RCA) from Webster Equity Partners for $4.6 billion in cash. RCA is a leading management services organization of retina specialists, with nearly 300 specialists across 23 states conducting over 2 million patient visits annually. Cencora will hold approximately 85% ownership, while RCA's affiliated practices, physicians, and management will retain a minority interest. The acquisition is expected to be $0.35 accretive to Cencora's adjusted diluted EPS in its first twelve months and includes potential contingent payments up to $500 million in fiscal years 2027 and 2028.

Cencora (NYSE: COR) announced two key appointments to its enterprise leadership team. Francois Mandeville joins as Executive Vice President, Strategy and M&A, bringing extensive experience from Johnson Controls and Danaher , where he helped grow business from $2.2B to $15B. Pawan Verma becomes Executive Vice President, Chief Data and Information Officer, joining from MetLife where he led a 10,000-person organization as Global CIO. These appointments aim to advance Cencora's pharmaceutical-centric strategy, enhance digital transformation, and drive growth through M&A and technological innovation.

Cencora, Inc. (NYSE: COR) has announced the date for its Fourth Quarter Fiscal 2024 Earnings Release. The company will release its results on Wednesday, November 6, 2024, before the New York Stock Exchange opens. A conference call to discuss the results is scheduled for 8:30 a.m. ET on the same day.

The call will feature Robert P. Mauch, President & CEO, and James F. Cleary, Executive VP & CFO. Investors can access the live webcast via investor.cencora.com. For telephone access, US and Canada participants should dial (833) 470-1428, while international callers should use +1 (404) 975-4839, with access code 272044.

Replays will be available via webcast and telephone. Cencora, ranked #10 on the Fortune 500, is a global pharmaceutical solutions organization with over $250 billion in annual revenue.

Frazier Healthcare Partners, a private equity firm focused on healthcare, has announced that Willis Chandler has joined their Growth Buyout team as an Executive in Residence. Chandler will help develop and execute investment strategies in pharma and pharmacy services, focusing on sourcing, diligence, and leadership of a new platform investment.

Chandler brings extensive experience, having most recently served as President of Global Pharma Services at Cencora (NYSE: COR), where he led a multi-billion dollar business unit with 10,000 employees. His background includes leadership roles at CVS Health and co-founding Shields Specialty Pharmacy. Chandler's expertise in entrepreneurial leadership, commercial transformation, and acquisition integration is expected to be valuable in Frazier's efforts to invest in disruptive growth-oriented healthcare companies.

Cencora, Inc. (NYSE: COR) has announced the election of Frank Clyburn to its Board of Directors, effective October 1, 2024. This addition will increase the board to thirteen members. Mr. Clyburn, a seasoned executive with extensive experience in the pharmaceutical industry, most recently served as CEO and board member of International Flavors and Fragrances Inc. His background includes leadership roles at major pharmaceutical manufacturers, notably as Executive Vice President and President of Human Health at Merck. Cencora's leadership, including Lead Independent Director Mark Durcan and Chairman, President & CEO Steven H. Collis, expressed confidence that Mr. Clyburn's expertise will contribute to the company's long-term growth and pharmaceutical-centric strategy.